AKBA News and Press, Akebia Therapeutics Inc. From 08/07/25

2025-08-07 19:34:39 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Be...

2025-08-07 19:34:09 ET Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Conference Call August 07, 2025 08:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director M...

2025-08-07 07:15:41 ET More on Akebia Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying Akebia Q2 2025 Earnings Preview Seeking Alpha&...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

Continued Vafseo ® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million ; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an oper...

Akebia Therapeutics Inc. (AKBA) is expected to report $-0.02 for Q2 2025

2025-08-06 18:00:16 ET Major earnings expected before the bell on Thursday include: Viatris ( VTRS ) Eli Lilly and Company ( LLY ) ConocoPhillips ( COP ) Datadog ( DDOG ) Warner Bros. Discovery ( WBD ) Read the full article on Seeking Alpha ...

2025-08-06 12:15:34 ET More on Akebia Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call...

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, wi...

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential ...